Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 453-457

  Clemons, Mark ^a,b   Russell, Kent ^a   Costa, Luis ^c   Addison, Christina L ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Adjuvant therapy; Bisphosphonate; Breast cancer; Clinical trials

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; TOREMIFENE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR BIOPSY;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 84868203206     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2077-6     Document Type: Review

References (20)

1. Amir E, Ocana A, Seruga B, Josse R, Clemons M (2010) Medical oncology: zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev 7:187-188
2. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85
3. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590
4. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405
5. Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49:42-49
6. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007-2011
7. Eidtmann H, De Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, Von Minckwitz G, Miller J, Schenk N, Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194
8. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky P, Jakesz R, Singer C, Eidtmann H, Fesl C, Eiermann W, Marth C, Greil R (2011) Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. In: San Antonio breast cancer symposium. San Antonio, TX
10. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjold B, Bergh J (2008) Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740-746
11. Mobus V, Thomssen C, Harbeck N, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Schneeweiss A, Kreienberg R, Huober J, Muller V, Luck H-J, Bauerfeind I, Loibl S, Nekljudova V, Von Minckwitz G (2011) GAIN (German Adjuvant Intergroup Node Positive) study: a phase III-multicenter trial to compare dose dense, dose intense ETC. (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer-1st interim efficacy analysis. In: CTRC-AACR (ed) San Antonio breast cancer symposium. San Antonio, TX
12. Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802
13. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178
14. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamaounas EP, Wolmark N (2011) NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. In: CTRC-AACR (ed) San Antonio breast cancer symposium. San Antonio, TX
15. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13
16. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581
17. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C (2004) Tenyear follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656
18. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557
19. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T (1998) Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 77:279-285
20. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988